BioXcel Therapeutics, Inc.
NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATION

Abstract:

The present disclosure provides a regimen for treating a subject afflicted with prostate cancer by administering Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab. The present disclosure is based on the discovery that the combination of Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab in a specific treatment regimen is a very effective therapy to treat subjects afflicted with prostate cancer.